Affini-T Raises $175m For Bicoastal TCR Play Focused On KRAS-Mutated Solid Tumors
With Vida Ventures and Leaps by Bayer leading the round, Affini-T raises $175m to advance its KRAS-targeted T-cell therapies into the clinic and add technological capabilities.
You may also be interested in...
ElevateBio Raises $401m To Fund Its Own And Partners’ Future Cell And Gene Therapy Needs
ElevateBio closed a series D venture capital round and revealed a potentially multibillion-dollar deal between its Life Edit subsidiary and Novo Nordisk as demand for its cell and gene therapy capabilities grow.
Mirati Spies ‘First-In-Class’ Chance For KRAS Inhibitor In Pancreatic Cancer
While chasing Amgen’s Lumakras in NSCLC, Mirati looks to now have an edge in two other tumor types.
Amgen Wins World-First Lumakras Approval, Faces Challenge Of COVID-Era Launch
Commercial EVP Murdo Gordon said launching sotorasib during the pandemic is a tougher challenge than encouraging doctors to screen lung cancer patients for KRAS G12C mutations and raising patient awareness.